Alcohol Use Disorder (AUD) – Market Access and Reimbursement Insights Report – 2025
Alcohol Use Disorder (AUD) Market Access and Reimbursement Insights
Thelansis’s “Alcohol
Use Disorder (AUD) Market Access and Reimbursement Insights Report –
2025″ provides comprehensive payer insights on the current and evolving
market access and reimbursement environments for branded and emerging drugs in
the indication. Our team understands the criticality of payer research and
insights generation, as well as their importance during drug development,
pre-market launch strategy, and post-marketing activities.
Alcohol Use
Disorder (AUD) Overview
Alcohol use disorder (AUD) is a
pathological condition characterized by persistent and excessive alcohol
consumption, leading to a diminished ability to limit or abstain from alcohol
use despite adverse consequences in one’s social, occupational, or medical
domain. The disorder is characterized by several key symptoms, including
craving, which is an intense urge to consume alcohol; loss of control, an
inability to cease alcohol consumption once initiated; and a negative emotional
state, feelings of anxiety and irritability when abstaining from alcohol.
Several factors increase the chances of developing an alcohol use disorder,
such as family history of substance abuse and alcohol use disorder, the
accessibility of alcohol, excessive alcohol consumption, binge drinking,
permissive cultural attitudes toward alcohol, childhood abuse, childhood
conduct or mood disorders, co-occurring mental health conditions such as
depression and PTSD, and impulsivity.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by surveys* and interviews with payers (e.g.,
pharmacy directors / medical directors from managed care organizations with
Medicare and/or Commercial plans in the United States). If required, primary
market research with physicians is also done to understand the impact of
reimbursement environment on treatment decisions for current and emerging
brands.
*Survey and
interview discussion guide are customized based on client requirements
Deliverables
format:
- PowerPoint presentation
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Key business
questions answered:
- Market access and reimbursement for
current therapies
- Coverage on
plans
- Market access
restrictions
- Rebates and
contracting
- Factors
influencing formulary access
- HEOR
requirements and influence, etc.
- Expected market access and
reimbursement for key emerging therapies
- Level of
awareness
- Anticipated
coverage on plans
- Factors that
would improve market access
- Pricing, etc.
- Impact on brand use
- Key factors
driving and limiting brand use
- Best and worst
performers on market access, etc.
- Evolving environment
- Payer
expectations from emerging therapies
- New policies and
their expected impact, etc.
- Advise to drug
manufacturers and developers
Read more: Alcohol Use Disorder (AUD) – Market Access and
Reimbursement Insights Report – 2025
Comments
Post a Comment